Cargando…

Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors

Dyslipidemia, highly elevated, low-density lipoprotein (LDL) cholesterol, is a major cardiovascular risk factor. Statins have been proven to effectively reduce the risk of atherosclerotic cardiovascular disease (ASCVD) and are recommended as a first-line therapy for the primary and secondary prevent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Jah Yeon, Na, Jin Oh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Lipidology and Atherosclerosis 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379114/ https://www.ncbi.nlm.nih.gov/pubmed/32821708 http://dx.doi.org/10.12997/jla.2019.8.2.183

Ejemplares similares

The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function
por: Di Costanzo, Assunta, et al.
Publicado: (2023)

Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
por: LaFratte, Christopher, et al.
Publicado: (2023)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms
por: Xu, Rui-Xia, et al.
Publicado: (2015)

Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?
por: Barkas, Fotios, et al.
Publicado: (2021)

Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting
por: Korman, Max, et al.
Publicado: (2018)

Combination therapy in cholesterol reduction: focus on ezetimibe and statins
por: Grigore, Liliana, et al.
Publicado: (2008)

The combination of Ezetimibe and Statin: a new treatment for hypercholesterolemia
por: NODARI, SAVINA, et al.
Publicado: (2007)

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
por: Hamilton-Craig, Ian, et al.
Publicado: (2010)

Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels
por: Berthold, Heiner K., et al.
Publicado: (2013)

PCSK9 Inhibitors: What Lies Beyond Monoclonal Antibodies?
por: EBioMedicine
Publicado: (2015)

Adding ezetimibe to statin therapy: latest evidence and clinical implications
por: Vavlukis, Marija, et al.
Publicado: (2018)

Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
por: Lee, Jeongmin, et al.
Publicado: (2023)

Statin and Ezetimibe Combination Therapy Decreases Mean Platelet Volume Compared to Statin Monotherapy
por: Lee, Jun-beom, et al.
Publicado: (2017)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

Pleiotropic Effects of PCSK-9 Inhibitors
por: Basiak, Marcin, et al.
Publicado: (2021)

Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers
por: Wu, Na-Qiong, et al.
Publicado: (2018)

Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation
por: Oh, Minyoung, et al.
Publicado: (2021)

May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?
por: Scicali, Roberto, et al.
Publicado: (2020)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
por: Péč, Martin Jozef, et al.
Publicado: (2023)

Influence of Previous Statin Therapy on Cholesterol-Lowering Effect of Ezetimibe
por: Choi, Young Hwan, et al.
Publicado: (2014)

Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study)
por: LIU, Yu-Qi, et al.
Publicado: (2021)

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
por: Mohamed, Farzahna, et al.
Publicado: (2023)

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
por: Mayne, Janice, et al.
Publicado: (2008)

Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
por: Sliz, Eeva, et al.
Publicado: (2018)

The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy
por: Ikegami, Yuichi, et al.
Publicado: (2018)

Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering
por: Bandyopadhyay, Dhrubajyoti, et al.
Publicado: (2018)

Safety and Tolerability of PCSK9 Inhibitors: Current Insights
por: Kosmas, Constantine E, et al.
Publicado: (2020)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
por: Pęczek, Piotr, et al.
Publicado: (2021)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
por: Seidah, Nabil G., et al.
Publicado: (2022)

The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases
por: Wan, Shuling, et al.
Publicado: (2021)

Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
por: Tomlinson, Brian, et al.
Publicado: (2021)

Intensive statin versus low-dose statin + ezetimibe treatment for fibrous cap thickness of coronary vulnerable plaques
por: Meng, Pei-Na, et al.
Publicado: (2020)

PCSK9 Inhibitors in a Statin-Intolerant Transgender Man With Heterozygous Familial Hypercholesterolemia: A Case Report
por: Pirazzi, Carlo, et al.
Publicado: (2019)

Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy
por: Kuyama, Naoto, et al.
Publicado: (2021)

The efficacy and safety of statin in combination with ezetimibe compared with double-dose statin in patients with high cardiovascular risk: A meta-analysis
por: Zhu, Yunyun, et al.
Publicado: (2020)

Case report: Intensive statin and PCSK-9 inhibitor combo reduces plaque volume and stenosis in ischemic stroke patient
por: Zeng, Weiqi, et al.
Publicado: (2023)

Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease
por: Schlackow, Iryna, et al.
Publicado: (2019)

Ezetimibe in Combination With a Statin Does Not Reduce All-Cause Mortality
por: Patel, Akshar Y., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_gemfkf65307na420i94fqrc97r